These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26502926)

  • 1. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
    Chamizo C; Zazo S; Dómine M; Cristóbal I; García-Foncillas J; Rojo F; Madoz-Gúrpide J
    BMC Pulm Med; 2015 Oct; 15():132. PubMed ID: 26502926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.
    Agulló-Ortuño MT; García-Ruiz I; Díaz-García CV; Enguita AB; Pardo-Marqués V; Prieto-García E; Ponce S; Iglesias L; Zugazagoitia J; López-Martín JA; Paz-Ares L; Nuñez JA
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):525-535. PubMed ID: 31832811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
    Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S
    Clin Transl Oncol; 2016 Jan; 18(1):107-12. PubMed ID: 26220094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.
    Shimizu T; Nakanishi Y; Nakagawa Y; Tsujino I; Takahashi N; Nemoto N; Hashimoto S
    Anticancer Res; 2012 Oct; 32(10):4589-96. PubMed ID: 23060591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
    Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J
    Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
    Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
    J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
    Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
    J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy.
    Yang M; Fan WF; Pu XL; Meng LJ; Wang J
    J Chemother; 2017 Apr; 29(2):106-112. PubMed ID: 27866454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).
    Kotoula V; Krikelis D; Karavasilis V; Koletsa T; Eleftheraki AG; Televantou D; Christodoulou C; Dimoudis S; Korantzis I; Pectasides D; Syrigos KN; Kosmidis PA; Fountzilas G
    BMC Cancer; 2012 Aug; 12():342. PubMed ID: 22866924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis.
    Wang T; Chuan Pan C; Rui Yu J; Long Y; Hong Cai X; De Yin X; Qiong Hao L; Li Luo L
    PLoS One; 2013; 8(9):e74284. PubMed ID: 24040222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.
    Fennell DA; Myrand SP; Nguyen TS; Ferry D; Kerr KM; Maxwell P; Moore SD; Visseren-Grul C; Das M; Nicolson MC
    PLoS One; 2014; 9(9):e107455. PubMed ID: 25250715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
    Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
    Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.
    Kanazawa K; Yokouchi H; Wang X; Ishida T; Fujita Y; Fujiuchi S; Harada T; Harada M; Takamura K; Oizumi S; Kinoshita I; Katsuura Y; Honjo O; Kojima T; Dosaka-Akita H; Isobe H; Munakata M; Nishimura M;
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1149-57. PubMed ID: 25294632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
    Liang Y; Wakelee HA; Neal JW
    Clin Lung Cancer; 2015 Sep; 16(5):366-73. PubMed ID: 25665893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.
    Igawa S; Sato Y; Ishihara M; Kasajima M; Kusuhara S; Nakahara Y; Otani S; Fukui T; Katagiri M; Sasaki J; Masuda N
    Asian Pac J Cancer Prev; 2016; 17(7):3249-53. PubMed ID: 27509958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
    Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
    Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Significance of Thymidylate Synthase Expression in Non-small Cell Lung Cancer.
    Kulda V; Hrda K; Houdek Z; Dobra JK; Vrzakova R; Svaton M; Safranek J; Dolezal J; Babuska V; Pesek M; Topolcan O; Pesta M
    Anticancer Res; 2017 Dec; 37(12):6953-6958. PubMed ID: 29187479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Zhao XM; Zhao J; Wu XH; Luo ZG; Wang HJ; Yu H; Chang JH; Wang JL
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):851-860. PubMed ID: 28755014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
    Hashemi Sadraei N; Feng Y; Du L; Fu P; Haque S; Dowlati A; Gollamudi J; Pennell NA; Mekhail T; Avril S; Farver C; Gerson SL; Sharma N
    Lung Cancer; 2018 Dec; 126():48-54. PubMed ID: 30527192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer.
    Igawa S; Sasaki J; Otani S; Shirasawa M; Niwa H; Kusuhara S; Harada S; Kubota M; Katagiri M; Masuda N
    Oncology; 2016; 91(1):41-7. PubMed ID: 27234033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.